Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Public ClinicalTrials.gov record NCT04981119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Observational Study Obtaining Solid Tumor Tissue From Participants and Apheresis for CAR T-Cell Therapy Manufacturing
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Study identification
- NCT ID
- NCT04981119
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 200 participants
Conditions and interventions
Conditions
- Solid Tumor, Adult
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Pancreatic Cancer
- CRC
- NSCLC
- Pancreas Cancer
- Mesothelioma
- Ovarian Cancer
- Ovarian Neoplasms
- Ovarian Carcinoma
- Mesothelioma, Malignant
- Mesothelioma; Lung
- Cancer
- Triple Negative Breast Cancer (TNBC)
- Renal Cell Carcinoma (Kidney Cancer)
- Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
- Apheresis Other
- Next Generation Sequencing (NGS) Diagnostic Test
- Long Range NGS HLA typing Diagnostic Test
Other · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2021
- Primary completion
- Nov 30, 2028
- Completion
- Mar 31, 2029
- Last update posted
- Jun 1, 2026
2021 – 2029
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Health | Gilbert | Arizona | 85234 | Recruiting |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | Recruiting |
| City of Hope | Duarte | California | 90101 | Completed |
| University of California San Diego | La Jolla | California | 92093 | Recruiting |
| Stanford University | Palo Alto | California | 94304 | Recruiting |
| UCLA Medical Center | Santa Monica | California | 90404 | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33136 | Recruiting |
| Massachusetts General Hospital/Dana Farber Cancer Institute | Boston | Massachusetts | 02114 | Completed |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | Recruiting |
| Washington University | St Louis | Missouri | 63110 | Recruiting |
| NYU Langone Medical Center | New York | New York | 10016 | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Completed |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04981119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04981119 live on ClinicalTrials.gov.